Patents by Inventor James F. Blake

James F. Blake has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS
    Publication number: 20190127373
    Abstract: Provided herein are compounds of the General Formula I: and stereoisomers and pharmaceutically acceptable salts or solvates thereof, in which A, B, D, E, X1, X2, X3 and X4 have the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including diseases or disorders mediated by a RET kinase.
    Type: Application
    Filed: January 7, 2019
    Publication date: May 2, 2019
    Inventors: Steven W. Andrews, James F. Blake, Mark J. Chicarelli, Adam Golos, Julia Haas, Yutong Jiang, Gabrielle R. Kolakowski
  • SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS
    Publication number: 20190127375
    Abstract: Provided herein are compounds of the General Formula I: and stereoisomers and pharmaceutically acceptable salts or solvates thereof, in which A, B, D, E, X1, X2, X3 and X4 have the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including diseases or disorders mediated by a RET kinase.
    Type: Application
    Filed: January 10, 2019
    Publication date: May 2, 2019
    Inventors: Steven W. Andrews, James F. Blake, Mark J. Chicarelli, Adam Golos, Julia Haas, Yutong Jiang, Gabrielle R. Kolakowski
  • SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS
    Publication number: 20190127374
    Abstract: Provided herein are compounds of the General Formula I: and stereoisomers and pharmaceutically acceptable salts or solvates thereof, in which A, B, D, E, X1, X2, X3 and X4 have the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including diseases or disorders mediated by a RET kinase.
    Type: Application
    Filed: January 7, 2019
    Publication date: May 2, 2019
    Inventors: Steven W. Andrews, James F. Blake, Mark J. Chicarelli, Adam Golos, Julia Haas, Yutong Jiang, Gabrielle R. Kolakowski
  • MACROCYCLIC COMPOUNDS AS ROS1 KINASE INHIBITORS
    Publication number: 20190076437
    Abstract: Methods for inhibiting a ROS1 kinase with compounds of Formula I: and pharmaceutically acceptable salts thereof, wherein ring A, ring B, W, m, D, R2, R2a, R3, R3a, and Z are as defined herein. The compounds and methods provided herein are useful in the treatment of cancer (e.g., ROS1-associated cancers as defined herein).
    Type: Application
    Filed: November 26, 2018
    Publication date: March 14, 2019
    Inventors: Steven W. Andrews, James F. Blake, Julia Haas, Gabrielle R. Kolakowski
  • MACROCYCLIC COMPOUNDS AS ROS1 KINASE INHIBITORS
    Publication number: 20190076436
    Abstract: Methods for inhibiting a ROS1 kinase with compounds of Formula I: and pharmaceutically acceptable salts thereof, wherein ring A, ring B, W, m, D, R2, R2a, R3, R3a, and Z are as defined herein. The compounds and methods provided herein are useful in the treatment of cancer (e.g., ROS1-associated cancers as defined herein).
    Type: Application
    Filed: November 26, 2018
    Publication date: March 14, 2019
    Inventors: Steven W. Andrews, James F. Blake, Julia Haas, Gabrielle R. Kolakowski
  • KRAS G12C INHIBITORS
    Publication number: 20190062330
    Abstract: The present invention relates to compounds that inhibit KRas G12C. In particular, the present invention relates to compounds that irreversibly inhibit the activity of KRas G12C, pharmaceutical compositions comprising the compounds and methods of use therefor.
    Type: Application
    Filed: October 29, 2018
    Publication date: February 28, 2019
    Inventors: James F. Blake, Laurence E. Burgess, Mark Joseph Chicarelli, James Gail Christensen, Jay Bradford Fell, John P. Fischer, John J. Gaudino, Erik James Hicken, Ronald Jay Hinklin, Matthew Randolf Lee, Matthew Arnold Marx, Macedonio J. Mejia, Martha E. Rodriguez, Pavel Savechenkov, Tony P. Tang, Guy P.A. Vigers, Henry J. Zecca
  • 2-aryl- and 2-heteroaryl-substituted 2-pyridazin-3(2H)-one compounds as inhibitors of FGFR tyrosine kinases
    Patent number: 10208024
    Abstract: Provided herein are compounds of the general Formula I: and stereoisomers and pharmaceutically acceptable salts or solvates thereof, in which X, R1, R2, R3, Ring A and z have the meanings given in the specification, which are inhibitors of FGFR1, FGFR2, FGFR3 and/or FGFR4 and are useful in the treatment and prevention of diseases which can be treated with an FGFR inhibitor, including diseases or disorders mediated by FGFR1, FGFR2, FGFR3 and/or FGFR4.
    Type: Grant
    Filed: October 24, 2016
    Date of Patent: February 19, 2019
    Assignee: Array BioPharma Inc.
    Inventors: Steven W. Andrews, James F. Blake, Adam Cook, Indrani W. Gunawardana, Kevin W. Hunt, Andrew T. Metcalf, David Moreno, Li Ren, Tony P. Tang
  • Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors
    Patent number: 10172851
    Abstract: Provided herein are compounds of the Formula I: and stereoisomers and pharmaceutically acceptable salts or solvates thereof, in which A, B, X1, X2, X3, X4, Ring D, and E have the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including RET-associated diseases and disorders.
    Type: Grant
    Filed: January 3, 2018
    Date of Patent: January 8, 2019
    Assignee: Array BioPharma Inc.
    Inventors: Steven W. Andrews, Sean Aronow, James F. Blake, Barbara J. Brandhuber, Adam Cook, Julia Haas, Yutong Jiang, Gabrielle R. Kolakowski, Elizabeth A. McFaddin, Megan L. McKenney, Oren T. McNulty, Andrew T. Metcalf, David A. Moreno, Tony P. Tang, Li Ren
  • Substituted pyrazolo[1,5-a]pyridine compounds as RET kinase inhibitors
    Patent number: 10174027
    Abstract: Provided herein are compounds of the General Formula I: and stereoisomers and pharmaceutically acceptable salts or solvates thereof, in which A, B, D, E, X1, X2, X3 and X4 have the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including diseases or disorders mediated by a RET kinase.
    Type: Grant
    Filed: December 29, 2017
    Date of Patent: January 8, 2019
    Assignee: Array BioPharma Inc.
    Inventors: Steven W. Andrews, James F. Blake, Mark J. Chicarelli, Adam Golos, Julia Haas, Yutong Jiang, Gabrielle R. Kolakowski
  • Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors
    Patent number: 10172845
    Abstract: Provided herein are compounds of the Formula I: or pharmaceutically acceptable salt or solvate thereof, wherein A, B, X1, X2, X3, X4, Ring D, E, Ra, Rb, n and m have the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including RET-associated diseases and disorders.
    Type: Grant
    Filed: January 3, 2018
    Date of Patent: January 8, 2019
    Assignee: Array BioPharma Inc.
    Inventors: Steven W. Andrews, Sean Aronow, James F. Blake, Barbara J. Brandhuber, James Collier, Adam Cook, Julia Haas, Yutong Jiang, Gabrielle R. Kolakowski, Elizabeth A. McFaddin, Megan L. McKenney, Oren T. McNulty, Andrew T. Metcalf, David A. Moreno, Ginelle A. Ramann, Tony P. Tang, Li Ren, Shane M. Walls
  • Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors
    Patent number: 10174028
    Abstract: Provided herein are compounds of the General Formula I: and stereoisomers and pharmaceutically acceptable salts or solvates thereof, in which A, B, D, E, X1, X2, X3 and X4 have the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including diseases or disorders mediated by a RET kinase.
    Type: Grant
    Filed: January 3, 2018
    Date of Patent: January 8, 2019
    Assignee: Array BioPharma Inc.
    Inventors: Steven W. Andrews, James F. Blake, Mark J. Chicarelli, Adam Golos, Julia Haas, Yutong Jiang, Gabrielle R. Kolakowski
  • Serine/threonine kinase inhibitors
    Patent number: 10154995
    Abstract: Compounds of Formula I or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof are provided, which are useful for the treatment of hyperproliferative, pain and inflammatory diseases. Methods of using compounds of Formula I or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed.
    Type: Grant
    Filed: August 23, 2017
    Date of Patent: December 18, 2018
    Assignees: Array BioPharma Inc., Genentech, Inc.
    Inventors: James F. Blake, Adam Cook, Indrani W. Gunawardana, Kevin W. Hunt, Michael Lyon, Andrew T. Metcalf, Peter J. Mohr, David A. Moreno, Brad Newhouse, Li Ren, Tony P. Tang, Allen A. Thomas, Jacob Schwarz, Jane Schmidt, Lewis Gazzard, Huifen Chen
  • Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors
    Patent number: 10144734
    Abstract: Provided herein are compounds of the Formula I: or pharmaceutically acceptable salt or solvate thereof, wherein A, B, X1, X2, X3, X4, Ring D, E, Ra, Rb, n and m have the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including RET-associated diseases and disorders.
    Type: Grant
    Filed: December 29, 2017
    Date of Patent: December 4, 2018
    Assignee: Array BioPharma Inc.
    Inventors: Steven W. Andrews, Sean Aronow, James F. Blake, Barbara J. Brandhuber, James Collier, Adam Cook, Julia Haas, Yutong Jiang, Gabrielle R. Kolakowski, Elizabeth A. McFaddin, Megan L. McKenney, Oren T. McNulty, Andrew T. Metcalf, David A. Moreno, Ginelle A. Ramann, Tony P. Tang, Li Ren, Shane M. Walls
  • Substituted pyrazolo[1,5-a]pyridine compounds as RET kinase inhibitors
    Patent number: 10138243
    Abstract: Provided herein are compounds of the General Formula I: and stereoisomers and pharmaceutically acceptable salts or solvates thereof, in which A, B, D, E, X1, X2, X3 and X4 have the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including diseases or disorders mediated by a RET kinase.
    Type: Grant
    Filed: January 3, 2018
    Date of Patent: November 27, 2018
    Assignee: Array BioPharma Inc.
    Inventors: Steven W. Andrews, James F. Blake, Mark J. Chicarelli, Adam Golos, Julia Haas, Yutong Jiang, Gabrielle R. Kolakowski
  • Substituted pyrazolo[1,5-a]pyridine compounds as RET kinase inhibitors
    Patent number: 10137124
    Abstract: Provided herein are compounds of the Formula I: and stereoisomers and pharmaceutically acceptable salts or solvates thereof, in which A, B, X1, X2, X3, X4, Ring D, and E have the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including RET-associated diseases and disorders.
    Type: Grant
    Filed: January 3, 2018
    Date of Patent: November 27, 2018
    Assignee: Array BioPharma Inc.
    Inventors: Steven W. Andrews, Sean Aronow, James F. Blake, Barbara J. Brandhuber, Adam Cook, Julia Haas, Yutong Jiang, Gabrielle R. Kolakowski, Elizabeth A. McFaddin, Megan L. McKenney, Oren T. McNulty, Andrew T. Metcalf, David A. Moreno, Tony P. Tang, Li Ren
  • PYRROLIDINYL UREA, PYRROLIDINYL THIOUREA AND PYRROLIDINYL GUANIDINE COMPOUNDS AS TRKA KINASE INHIBITORS
    Publication number: 20180334450
    Abstract: Compounds of Formula I: or stereoisomers, tautomers, or pharmaceutically acceptable salts, or solvates or prodrugs thereof, where R1, R2, Ra, Rb, Rc, Rd, X, Y, B, and Ring C are as defined herein, and wherein the Y—B moiety and the NH—C(?X)—NH moiety are in the trans configuration, are inhibitors of TrkA kinase and are useful in the treatment of diseases which can be treated with a TrkA kinase inhibitor such as pain, cancer, inflammation, neurodegenerative diseases and certain infectious diseases.
    Type: Application
    Filed: December 12, 2017
    Publication date: November 22, 2018
    Applicant: Array BioPharma Inc.
    Inventors: Shelley Allen, Steven W. Andrews, James F. Blake, Kevin R. Condroski, Julia Haas, Lily Huang, Yutong Jiang, Timothy Kercher, Gabrielle R. Kolakowski, Jeongbeob Seo
  • KRas G12C inhibitors
    Patent number: 10125134
    Abstract: The present invention relates to compounds that inhibit KRas G12C. In particular, the present invention relates to compounds that irreversibly inhibit the activity of KRas G12C, pharmaceutical compositions comprising the compounds and methods of use therefor.
    Type: Grant
    Filed: November 15, 2017
    Date of Patent: November 13, 2018
    Assignees: MIRATI THERAPEUTICS, INC., ARRAY BIOPHARMA INC.
    Inventors: James F. Blake, Laurence E. Burgess, Mark Joseph Chicarelli, James Gail Christensen, Jay Bradford Fell, John P. Fischer, John J. Gaudino, Erik James Hicken, Ronald Jay Hinklin, Matthew Randolf Lee, Matthew Arnold Marx, Macedonio J. Mejia, Martha E. Rodriguez, Pavel Savechenkov, Tony P. Tang, Guy P. A. Vigers, Henry J. Zecca
  • Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors
    Patent number: 10112942
    Abstract: Provided herein are compounds of the Formula I: and stereoisomers and pharmaceutically acceptable salts or solvates thereof, in which A, B, X1, X2, X3, X4, Ring D, and E have the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including RET-associated diseases and disorders.
    Type: Grant
    Filed: December 29, 2017
    Date of Patent: October 30, 2018
    Assignee: Array BioPharma Inc.
    Inventors: Steven W. Andrews, Sean Aronow, James F. Blake, Barbara J. Brandhuber, Adam Cook, Julia Haas, Yutong Jiang, Gabrielle R. Kolakowski, Elizabeth A. McFaddin, Megan L. McKenney, Oren T. McNulty, Andrew T. Metcalf, David A. Moreno, Tony P. Tang, Li Ren
  • Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors
    Patent number: 10023570
    Abstract: Provided herein are compounds of the General Formula I: and stereoisomers and pharmaceutically acceptable salts or solvates thereof, in which A, B, D, E, X1, X2, X3 and X4 have the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including diseases or disorders mediated by a RET kinase.
    Type: Grant
    Filed: July 15, 2016
    Date of Patent: July 17, 2018
    Assignee: Array BioPharma Inc.
    Inventors: Steven W. Andrews, James F. Blake, Mark J. Chicarelli, Adam Golos, Julia Haas, Yutong Jiang, Gabrielle R. Kolakowski
  • SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS
    Publication number: 20180186791
    Abstract: Provided herein are compounds of the General Formula I: and stereoisomers and pharmaceutically acceptable salts or solvates thereof, in which A, B, D, E, X1, X2, X3 and X4 have the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including diseases or disorders mediated by a RET kinase.
    Type: Application
    Filed: January 3, 2018
    Publication date: July 5, 2018
    Inventors: Steven W. Andrews, James F. Blake, Mark J. Chicarelli, Adam Golos, Julia Haas, Yutong Jiang, Gabrielle R. Kolakowski